Finastid

• Anti-baldness Agents
• Antihyperplasia Agents
• Skin and Mucous Membrane Agents (84:92.00)
• ATC:D11AX10
• ATC:G04CB01

• Chibro-Proscar
• Finasterida [Inn-Spanish]
• Finasteride [Usan:Ban:Inn]
• Finasteride and Its Intermediates
• Finasteridum [Inn-Latin]
• Finastid
• Finpecia
• Propecia
• Proscar
• Prostide

• No information avaliable

C₂₃H₃₆N₂O₂

http://www.rxlist.com/cgi/generic3/propecia.htm

Finastid FDA

No information avaliable

372.544 g/mol

252-254 ^oC

11.7 mg/L

Solid

4.277

Tablet

For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: Improve symptoms, reduce the risk of acute urinary retention, reduce the risk of the need for surgery including transurethral resection of the prostat.

Finasteride is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only. Finasteride is a competitive and specific inhibitor of Type II 5a-reductase, an intracellular enzyme that converts the androgen testosterone into DHT. Two distinct isozymes are found in mice, rats, monkeys, and humans: Type I and II. Each of these isozymes is differentially expressed in tissues and developmental stages. In humans, Type I 5a-reductase is predominant in the sebaceous glands of most regions of skin, including scalp, and liver. Type I 5a-reductase is responsible for approximately one-third of circulating DHT. The Type II 5a-reductase isozyme is primarily found in prostate, seminal vesicles, epididymides, and hair follicles as well as liver, and is responsible for two-thirds of circulating DHT.

No information avaliable

No information avaliable

No information avaliable

Humans and other mammals